Abstract
Background: Human immunodeficiency virus (HIV)-associated tuberculosis is difficult to treat, given the propensity for drug interactions between the rifamycins and the antiretroviral drugs. We examined the pharmacokinetics of rifabutin before and after the addition of lopinavir-ritonavir. Methods: We analyzed 10 patients with HIV infection and active tuberculosis in a state tuberculosis hospital. Plasma was collected for measurement of rifabutin, the microbiologically active 25-desacetyl-rifabutin, and lopinavir by validated high-performance liquid chromatography assays. Samples were collected 2-4 weeks after starting rifabutin at 300 mg thrice weekly without lopinavir-ritonavir, 2 weeks after the addition of lopinavir-ritonavir at 400 and 100 mg, respectively, twice daily to rifabutin at 150 mg thrice weekly, and (if rifabutin plasma concentrations were below the normal range) 2 weeks after an increase in rifabutin to 300 mg thrice weekly with lopinavirritonavir.Noncompartmental and population pharmacokinetic analyses (2-compartment open model) were performed. Results: Rifabutin at 300 mg without lopinavir-ritonavir produced a low maximum plasma concentration (Cmax) in 5 of 10 patients. After the addition of lopinavir-ritonavir to rifabutin at 150 mg, 9 of 10 had low Cmax values. Eight patients had dose increases to 300 mg of rifabutin with lopinavir-ritonavir. Most free rifabutin (unbound to plasma protein) Cmax values were below the tuberculosis minimal inhibitory concentration. For most patients, values for the area under the plasma concentration-time curve were as low or lower than those associated with treatment failure or relapse and with acquired rifamycin resistance in Tuberculosis Trials Consortium/US Public Health Service Study 23. One of the 10 patients experienced relapse with acquired rifamycin resistance. Conclusion. The recommended rifabutin doses for use with lopinavir-ritonavir may be inadequate in many patients. Monitoring of plasma concentrations is recommended.
| Original language | English |
|---|---|
| Pages (from-to) | 1305-1311 |
| Number of pages | 7 |
| Journal | Clinical Infectious Diseases |
| Volume | 49 |
| Issue number | 9 |
| DOIs | |
| State | Published - Nov 1 2009 |
Fingerprint
ASJC Scopus subject areas
- Infectious Diseases
- Microbiology (medical)
Cite this
Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with hiv infection and active tuberculosis. / Boulanger, Catherine V; Hollender, Elena; Farrell, Karen; Jean Stambaugh, Jerry; Maasen, Diane; Ashkin, David; Symes, Stephen; Espinoza, Luis; Rivero, Rafael O.; Graham, Jenny J.; Peloquin, Charles A.
In: Clinical Infectious Diseases, Vol. 49, No. 9, 01.11.2009, p. 1305-1311.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with hiv infection and active tuberculosis
AU - Boulanger, Catherine V
AU - Hollender, Elena
AU - Farrell, Karen
AU - Jean Stambaugh, Jerry
AU - Maasen, Diane
AU - Ashkin, David
AU - Symes, Stephen
AU - Espinoza, Luis
AU - Rivero, Rafael O.
AU - Graham, Jenny J.
AU - Peloquin, Charles A.
PY - 2009/11/1
Y1 - 2009/11/1
N2 - Background: Human immunodeficiency virus (HIV)-associated tuberculosis is difficult to treat, given the propensity for drug interactions between the rifamycins and the antiretroviral drugs. We examined the pharmacokinetics of rifabutin before and after the addition of lopinavir-ritonavir. Methods: We analyzed 10 patients with HIV infection and active tuberculosis in a state tuberculosis hospital. Plasma was collected for measurement of rifabutin, the microbiologically active 25-desacetyl-rifabutin, and lopinavir by validated high-performance liquid chromatography assays. Samples were collected 2-4 weeks after starting rifabutin at 300 mg thrice weekly without lopinavir-ritonavir, 2 weeks after the addition of lopinavir-ritonavir at 400 and 100 mg, respectively, twice daily to rifabutin at 150 mg thrice weekly, and (if rifabutin plasma concentrations were below the normal range) 2 weeks after an increase in rifabutin to 300 mg thrice weekly with lopinavirritonavir.Noncompartmental and population pharmacokinetic analyses (2-compartment open model) were performed. Results: Rifabutin at 300 mg without lopinavir-ritonavir produced a low maximum plasma concentration (Cmax) in 5 of 10 patients. After the addition of lopinavir-ritonavir to rifabutin at 150 mg, 9 of 10 had low Cmax values. Eight patients had dose increases to 300 mg of rifabutin with lopinavir-ritonavir. Most free rifabutin (unbound to plasma protein) Cmax values were below the tuberculosis minimal inhibitory concentration. For most patients, values for the area under the plasma concentration-time curve were as low or lower than those associated with treatment failure or relapse and with acquired rifamycin resistance in Tuberculosis Trials Consortium/US Public Health Service Study 23. One of the 10 patients experienced relapse with acquired rifamycin resistance. Conclusion. The recommended rifabutin doses for use with lopinavir-ritonavir may be inadequate in many patients. Monitoring of plasma concentrations is recommended.
AB - Background: Human immunodeficiency virus (HIV)-associated tuberculosis is difficult to treat, given the propensity for drug interactions between the rifamycins and the antiretroviral drugs. We examined the pharmacokinetics of rifabutin before and after the addition of lopinavir-ritonavir. Methods: We analyzed 10 patients with HIV infection and active tuberculosis in a state tuberculosis hospital. Plasma was collected for measurement of rifabutin, the microbiologically active 25-desacetyl-rifabutin, and lopinavir by validated high-performance liquid chromatography assays. Samples were collected 2-4 weeks after starting rifabutin at 300 mg thrice weekly without lopinavir-ritonavir, 2 weeks after the addition of lopinavir-ritonavir at 400 and 100 mg, respectively, twice daily to rifabutin at 150 mg thrice weekly, and (if rifabutin plasma concentrations were below the normal range) 2 weeks after an increase in rifabutin to 300 mg thrice weekly with lopinavirritonavir.Noncompartmental and population pharmacokinetic analyses (2-compartment open model) were performed. Results: Rifabutin at 300 mg without lopinavir-ritonavir produced a low maximum plasma concentration (Cmax) in 5 of 10 patients. After the addition of lopinavir-ritonavir to rifabutin at 150 mg, 9 of 10 had low Cmax values. Eight patients had dose increases to 300 mg of rifabutin with lopinavir-ritonavir. Most free rifabutin (unbound to plasma protein) Cmax values were below the tuberculosis minimal inhibitory concentration. For most patients, values for the area under the plasma concentration-time curve were as low or lower than those associated with treatment failure or relapse and with acquired rifamycin resistance in Tuberculosis Trials Consortium/US Public Health Service Study 23. One of the 10 patients experienced relapse with acquired rifamycin resistance. Conclusion. The recommended rifabutin doses for use with lopinavir-ritonavir may be inadequate in many patients. Monitoring of plasma concentrations is recommended.
UR - http://www.scopus.com/inward/record.url?scp=72849124759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72849124759&partnerID=8YFLogxK
U2 - 10.1086/606056
DO - 10.1086/606056
M3 - Article
C2 - 19807276
AN - SCOPUS:72849124759
VL - 49
SP - 1305
EP - 1311
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 9
ER -